Usefulness of Staging Chest CT in Breast Cancer: Evaluating Diagnostic Yield of Chest CT according to the Molecular Subtype and Clinical Stage

Journal of Clinical Medicine

Young-Sil An¹  TaeHee Kim²  JooSung Sun²  DooKyoung Kang²  Seulgi You²  KyungJoo Park² 

[1] Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon 16499, Korea;Department of Radiology, Ajou University School of Medicine, Suwon 16499, Korea;

关键词: staging chest CT;    breast cancer;    diagnostic yield;    molecular subtype;    clinical stage;   

DOI  :  10.3390/jcm10050906

来源: DOAJ

【 摘 要 】

The aim of this study is to investigate the clinical utility of staging chest CT in breast cancer by evaluating diagnostic yield (DY) of chest CT in detection of metastasis, according to the molecular subtype and clinical stage. This retrospective study included 840 patients with 855 breast cancers from January 2017 to December 2018. The number of patients in clinical stage 0/I, II, III and IV were 457 (53.5%), 298 (34.9%), 92 (10.8%) and 8 (0.9%), respectively. Molecular subtype was identified in 841 cancers and there were 709 (84.3%) luminal type, 55 (6.5%) human epidermal growth factor receptor 2 (HER2)-enriched type and 77 (9.2%) triple-negative (TN) type. The DYs in clinical stage 0/I, cII, cIII and cIV were 0.2% (1/457), 1.7% (5/298), 4.3% (4/92) and 100.0% (8/8), respectively. The DYs in luminal type, HER2-enriched type and TN type were 1.7% (12/709), 3.6% (2/55) and 2.6% (2/77), respectively. Clinical stage was associated with the DY (p = 0.000). However, molecular subtype was not related to the DY (p = 0.343). Molecular subtype could not provide useful information to determine whether staging chest CT should be performed in early-stage breast cancer. However, chest CT should be considered in advanced breast cancer.

【 授权许可】

Unknown